1. Case 1 11622357 박성진 M/66 adm. 2011.05.31 C.C) for TACE #2 P.I) 66/M CHB 로 2006 년부터 본원 IG f/u 중인자로 2006.01 HCC 진단 받고 TACE #1, 2008.02 RFA #1 시행한 자로 2011.05 liver MR 에서 HCC recur 소견 보여 TACE #2 위해 내원 PMHx) DM / HTN / pul.TB / hepatitis (-/+/-/+) :hepatitis B 2006 년 진단, 2009 년 HTN 진단 Medication(+) : Lamivudine 100mg, Adefovir 10mg, Carvedilol 25mg 1t qd OPHx) (-) PHx) alcohol(-), smoking(+): 30 packyear FHx) none

2. 2 CBC/DC WBC(mm 3 )4490 Hb(g/dl)13.2 PLT(mm 3 )153K PT(sec)13.2 INR1.04 Lab Findings (2011.07.28) 11622357 박성진 M/66 adm. 2011.05.31 Performance status Grade0 Tumor markers AFP (ng/mL)141 PIVKA II82 Chemistry TB/DB(mg/dL)0.53/0.19 AST/ALT(IU/L)25/21 ALP/rGT(IU/L)79/38 Prot/Alb(g/dL)8.1/4.6 BUN/Cr(mg/dL)16/1.0 LC & Stage Child-PughA(5) MELD score8 EV(-) ascites(-) encephalopathy(-) Viral markers HBsAg(+) Anti HBsAb(-) anti-HBe Ab(+) HBe Ag(+) Anti-viral agent(+)

3. Clinical Course HCC CHB 2006 2008.02 2011.05 2011.08 *Liver CT (2011.08.01) : Marked aggravation of partially lipiodolized HCC in segment 8. Suggested tumor thrombosis in right portal vein. Several new HCCs in caudate lobe and segment 8. Stable state of previously noted HCCs in segment 8 and segment 6, controlled by TACE or dysplastic nodule. AFP 2.74 ng/mL TACE #2 Liver MR AFP 1.84 ng/mL AFP 141 ng/mL AFP 554 ng/mL RFA TACE #1 HCC recur

4. Case 2 11053932 임일두 M/69 2011.08.01 C.C) for cancer staging P.I) M/69 2008 년 B-viral LC 진단 받고 medication 없이 외부병원 f/u 하 던자로 2011.02 월 본원에서 intrahepatic cholangiocarcinoma 진단 받 고 2011.03 본원 GS(pf 홍성화 ) 에서 Rt hemihepatectomy 시행 후 2011.07 GS 외래에서 촬영한 PET-CT 에서 aortocaval and pericaval area, RUQ peritoneum 에 LN metastasis, adrenal gl, parotid gl 에도 metastasis 의심되는 소견 보여 f/e 위하여 내원 PMHx) DM / HTN / pul.TB / hepatitis (-/-/-/+): 2008 년 b-viral LC 진단 2011.02 월 - intrahepatic cholagiocarcinoma 진단 Medication(-) OPHx) 2011.02 월 Rt hemihepatectomy PHx) alcohol(-) – 소주 1 병 /day smoking (-) ex-smoker – 10packyear FHx) none

5. CBC/DC WBC(mm 3 )3770 Hb(g/dl)13.2 PLT(mm 3 )123K PT(sec)13.1 INR1.03 Lab Findings (2010.08) 11053932 임일두 M/69 2011.08.01 Performance status Grade0 Tumor markers CEA (ng/mL)47.8 CEA9.59 Chemistry TB/DB(mg/dL)0.61/0.25 AST/ALT(IU/L)32/18 ALP/rGT(IU/L)137/152 Prot/Alb(g/dL)7.2/3.7 BUN/Cr(mg/dL)19/1.1 LC & Stage Child-PughA(5) MELD score5.8 EVunchecked ascites(-) encephalopathy(-) Viral markers HBsAg(+) Anti HBsAb(-) anti-HBe Ab(+) HBe Ag(-) Anti-viral agent(-)

6. Clinical Course B-viral LC 2008 2011.02 2011.07 2011.08 Abd, chest, Neck CT (2011.08.19) : Aggravation of retroperitoneal LNs metastases. Newly developed both adrenal metastases No significant change of size of the mass at superficial and deep lobes of right parotid gland (not exclude metastasis, R/O another salivary gland tumor such as pleomorphic adenoma, mucoepidermoid carcinoma) PET-CT aortocaval and pericaval area LN metastasis r/o adrenal gl, parotid gl meta aortocaval and pericaval area LN metastasis r/o adrenal gl, parotid gl meta Intrahepatic cholagiocarcinoma Rt hemihepatectomy Abd CT Chest CT Neck CT

7. Case 3 12024069 윤홍식 M/50 adm. 2011.03.18 C.C) for TACE #1 P.I) M/50 10 년전 Chronic hepatitis B 진단 받은자고 2009 년부터 본원 IG 에서 f/u 하면서 B-viral LC 진단 받고 2011.03 외래에서 시행한 liver CT 에서 2 개의 nodular HCCs 가 segment 8 과 segment 7/6 사시에 서 발견되어 TACE #1 위해 입원 PMHx) DM / HTN / pul.TB / hepatitis (-/-/+/+) :HBV 10 년전 진단 Tbc 1994 진단, 완치판정 Medication (+): 2011.02 부터 Entecavir 0.5mg 1T qd 복용중 OPHx) (-) PHx) alcohol(+) – 소주 2 병, 주 3 회 smoking(-) – Ex-smoker (20 갑년 ), 2001 년 부터 금연중 FHx) 모친 - 당뇨

8. 8 CBC/DC WBC(mm 3 )7420 Hb(g/dl)16 PLT(mm 3 )164K PT(sec)14.3 INR1.10 Lab Findings 12024069 윤홍식 M/50 adm. 2011.03.18 Performance status Grade0 Tumor markers AFP (ng/mL)16.53 Chemistry TB/DB(mg/dL)0.79/0.23 AST/ALT(IU/L)32/47 ALP/rGT(IU/L)65/73 Prot/Alb(g/dL)7.3/4.3 BUN/Cr(mg/dL)13/0.7 LC & Stage Child-PughA(5) MELD score3.19 EVUnchecked ascites(-) encephalopathy(-) Viral markers HBsAg(+) anti-HBe Ab(+) HBe Ag(-) Anti-viral agent(+)

9. Clinical Course CHB 2001 2009 2011.03 2011.05 2011.08 TACE #1 *Liver CT (2011.08.23) : Recurrent HCC at previous lipiodolized area of S5 (1cm). No definite recurrent tumor at S7 and S8 lipiodol-uptaken area. A 1.9cm persistent hypoattenuating nodular lesion at S6 periphery near MHV. - High grad DN vs. WD HCC. Multiple hemngiomas in both lobes of the liver, no significant change. Multiple DN or RNs in both lobe of the liver. Underlying LC. BPH. AFP 15.6 ng/mL B-viral LC HCC Liver MR AFP 16.5 ng/mL AFP 14.36 ng/mL Liver CT HCC recur

10. Case 4 12128040 정용기 M/51 adm. 2011.07.11 C.C) for TACE #3 P.I) 51 세 남자 환자 2010.07 B-viral LC with HCC 진단 받고 2010.07 TACE #1 시행 후 2011.02 이전 TACE 한 부위의 전하방측에 HCC recur 소견 있어 TACE #2 시행 한 자로 2010.06 에서 시행한 liver MRI 에서 Recurrent HCC at previous lipiodolized area of S5 소견 보여 TACE #3 위하여 입원. PMHx) DM / HTN / pul.TB / hepatitis (-/-/-/+): 2010.07 B-viral LC 진단 OPHx) (-) 2010.11 EVL #1 2011.01 EGD – EV F1-2 Medication (+) Entecavir 0.5mg 1t qd PHx) alcohol (-). smoking(-) - Ex smoker FHx) none

11. 11 CBC/DC WBC(mm 3 )3140 Hb(g/dl)13.2 PLT(mm 3 )42K PT(sec)16.3 INR1.37 Lab Findings 12128040 정용기 M/51 adm. 2011.07.11 Performance status Grade0 Tumor markers AFP (ng/mL)8879 Chemistry TB/DB(mg/dL)2.23/1.0 AST/ALT(IU/L)60/39 ALP/rGT(IU/L)127/94 Prot/Alb(g/dL)7.1/3.3 BUN/Cr(mg/dL)11/0.6 LC & Stage Child-PughB(8) MELD score8.1 EV(+), F1-2. post EVL scar ascites(-) encephalopathy(-) Viral markers HBsAg(+) Anti HBsAb(-) anti-HBe Ab(+) HBe Ag(+) Anti-viral agent(+)

12. Clinical Course HCC recur B-viral LC 2010.07 2011.02 2011.07 2011.08 AFP 8895 ng/mL *Liver CT (2011.08.22) : Recurrent HCC at dome area o f left lateral segment and recurrent HCC with malignant portal vein trhombus at left medial segment Multiple lipiodolized HCC at left latgeral segment of liver GB wall edema Rec;Liver MR. AFP 3622ng/mL AFP 6389 ng/mL Liver MR TACE #1 LiverCT HCC TACE #2 HCC recur TACE #3 HCC recur AFP 8879ng/mL